Trial Profile
Two-Part, Sequential Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TC-5619-238 in Elderly Subjects With and Without Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2013
Price :
$35
*
At a glance
- Drugs Bradanicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record